GENENTECH’S FARICIMAB MEETS ENDPOINTS IN MULTIPLE TRIALS
Genentech announced announced topline results from two identically designed global Phase III studies, TENAYA and LUCERNE, evaluating its investigational bispecific antibody, faricimab, in people with neovascular age-related macular degeneration. Both studies met their primary endpoint and showed that people receiving faricimab injections at fixed intervals of up to every 16 weeks achieved visual acuity outcomes that were non-inferior to those receiving aflibercept injections every eight weeks, the company says. Nearly half (45 percent) of people in both studies were treated with faricimab every 16 weeks during the first year.
Nanoscope Receives Orphan Drug Designation for Gene Therapy
Nanoscope Therapeutics received FDA Orphan Drug Designation for its gene therapy-based treatment of Stargardt’s disease. The therapy uses light-sensitive molecules to re-sensitize the retina toward ambient light level. Nanoscope’s pipeline includes optogenetics-based retinal regeneration therapy for vision restoration in patients with retinitis pigmentosa, Stargardt’s disease and dry age-related macular degeneration. Read more.
MeiraGTx’s AAV-CNGA3 Granted FDA Fast Track Designation for Achromatopsia Treatment
MeiraGTx announced the FDA granted Fast Track designation to its AAV-CNGA3 gene therapy product candidate for the treatment of achromatopsia (ACHM), caused by mutations in the CNGA3 gene. AAV-CNGA3 is an investigational gene therapy treatment designed to restore cone function, delivered to the cone receptors at the back of the eye via subretinal injection. Read more.
Nonprofit Partners with Genetics Company to Treat Blinding Diseases
In an effort to help medical researchers develop new treatments for blinding eye diseases, Advancing Sight Network and Kailos Genetics created the OcularGeneScreen, a genetic screening panel to be used with eye tissue from post-mortem eye donors, to help determine which genes are associated with eye diseases such as age-related macular degeneration, glaucoma and Fuchs’ Dystrophy. Read more.
Eyedaptic Augmented Reality Visual Aid Granted Patent
Eyedaptic announced it was granted the first of nine pending patents and that it launched an Equity Crowdfunding Campaign to introduce its visual aid solution to stakeholders in the eye-care and technology communities. Eyedaptic develops visual-aid software that it says enables a more complete field of vision and simulates natural vision for people with central vision disorders. Learn more.
J&J Vision Names Menziuso as Worldwide President for Vision Care
Johnson & Johnson Vision announced that Peter Menziuso is assuming the role of worldwide president, Vision Care, for Johnson & Johnson Vision immediately. Peter replaces Swami Raote, who retired at the end of 2020, after a 29-year tenure with Johnson & Johnson. Menziuso most recently served as president, Cardiovascular & Metabolism, Janssen, where he led the organization in its mission to advance cardiovascular and metabolic care.